back to top
HomeSHARE MARKET1300% Massive Return; Now Good News Comes; 250000 Shares Bought By Mutual...

1300% Massive Return; Now Good News Comes; 250000 Shares Bought By Mutual Fund; Share Will Double

Hot Stocks Alert Join

Kopran Ltd (NSE: KOPRAN): There has been a massive increase in shares of the small-cap pharma business Kopran Limited. Shares of Kopran Limited decrease by 1.85 percent on Tuesday to reach Rs 260.45.

The company’s shares have reached a one-month high. This rise in the shares of pharma company Kopran has come after a big bet by the leading mutual fund Quant. Quant Smallcap Fund on Friday bought a 0.5% stake in Kopran through bulk deals.

Quant Smallcap Fund Bought 250000 Shares

Quant Smallcap Fund on Friday bought 250000 shares of Kopran Limited. Quant has bought these shares for Rs 255.51 per share. At present, it is not known who has sold these shares. 

Kopran Limited is in the formulations and pharma API manufacturing business. The market capitalization that the business has is 12.80 billion. 

The Company’s Shares Rose By More Than 1300% In 4 Years

Shares of Kopran Limited have increased by more than 1300% in the last 4 years. Shares of the pharma company was at Rs 18.90 on March 27, 2020. 

The company’s share has reached Rs 260.45 on March 19, 2024. Over the past year, the shares of Kopran Limited have increased by more than 160%.

The shares of the company was at Rs 103.90 on March 20, 2023, which reached Rs 260.45 on March 19, 2024. The 52-week high level of shares of Kopran Limited is Rs 292.40. 

At the same time, the 52-week low level of the company’s shares is Rs 96. The all-time high of shares of Kopran Limited is Rs 375. 

The shares of the company was at the level of 18 April 1996. In the same way, the record low for the shares of the company is 6.

About Kopran Ltd Company 

Kopran Limited is an Indian company. It is an integrated pharmaceutical company.

The Company is principally engaged in the manufacturing of formulas (finished dosing in the form of) along with active pharmaceutical components (APIs).

The categories of its formulation products comprise penicillin-based finished oral dosage forms, as well as non-penicillin-based completed oral dosage formulations.

The Company’s penicillin-based orally administered dosages include antibiotics ampicillin, amoxicillin Cloxacillin, and Moxy club.

Its finished, non-penicillin-based dosages include macrolides and anti-hypertensive cardiovascular, anti-hermeneutics and antihistamine, anti-diabetic pain management, as well as gastroenterology.

It supplies ingredients in various pharmaceutical products, including capsules, injectables, as well as tablets, to name a few.

The Company’s API products include anti-hypertensive, macrolides, neuromodulators, anti-infective or anti-acne, sterile carbapenems, and sterile cephalosporins.

Fundamental Analysis of Kopran Ltd

Market Cap₹ 1,283 Cr.
Current Price₹ 260.45
52-wk High₹ 292 
52-wk Low₹ 96.0
Stock P/E31.8
Book Value₹ 91.6
Dividend1.13 %
ROCE8.30 %
ROE6.29 %
Face Value₹ 10.0
P/B Value2.90
OPM11.2 %
EPS₹ 8.37
Debt₹ 93.2 Cr.
Debt to Equity0.21

Kopran Ltd Share Price Target 2024 To 2030

Year1st Target2nd Target
Hot Stocks Alert Join

Kopran Ltd Shareholding Pattern

Promoters Holding
Dec 202244.29%
Mar 202344.29%
June 202344.49%
Sept 202344.49%
Dec 202344.49%
FII Holding
Dec 20220.34%
Mar 20230.41%
June 20230.34%
Sept 20230.39%
Dec 20230.48%
DII Holding
Dec 20220.14%
Mar 20230.14%
June 20230.14%
Sept 20230.35%
Dec 20230.14%
Hot Stocks Alert Join
Public Holding
Dec 202255.22%
Mar 202355.15%
June 202355.03%
Sept 202354.78%
Dec 202354.88%

Kopran Ltd Share: Last 5 Years’ Financial Condition

To better understand how the market is performing, let’s look at the outlook of this share in the previous years. 

However, investors should be aware of the risks and the market conditions before making any investment decision.

Last 5 Years’ Sales:

2019₹ 358 Cr
2020₹ 360 Cr
2021₹ 492 Cr
2022₹ 478 Cr
2023₹ 577 Cr

Last 5 Years’ Net Profit:

2019₹ 24 Cr
2020₹ 21 Cr
2021₹ 61 Cr
2022₹ 61 Cr
2023₹ 40 Cr
Hot Stocks Alert Join

Last 5 Years’ Debt-To-Equity Ratio:


Last 10 Years’ Profit Growth:

10 Years:9%
5 Years:6%
3 Years:8%
Current Year:10%

Last 10 years’ Return on Equity (ROE):

10 Years:15%
5 Years:15%
3 Years:15%
Last Year:6%

Sales Growth Over 10 Years:

10 Years:8%
5 Years:12%
3 Years:15%
Current Year:6%


This article is a complete guide about Kopran Ltd Share. This information and forecasts are based on our research, company fundamentals, history, experiences, and technical analyses. 

Also, We have discussed the share’s prospects and growth potential in detail.

This information will help you in your further investment. 

If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.

If you have any further queries, please comment below. We will be happy to answer all your questions. 

If you like this information, share the article with as many people as possible.



Please enter your comment!
Please enter your name here